What is the difference between Elacetrant and Everolimus? Which drug is more suitable for patients to use

Elacetrant is an oral selective estrogen receptor degrader (SERD), mainly used to treat hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. It inhibits the estrogen signaling pathway by selectively degrading the estrogen receptor (ER), thereby preventing the growth of cancer cells. In contrast, everolimus (Everolimus) is an oral mTOR inhibitor that works by blocking mTORsignaling pathway inhibits tumor cell proliferation and angiogenesis, and is usually used in combination with tamoxifen or aromatase inhibitors to treatHR+ breast cancer and certain solid tumors. The two have different targets and signaling pathways, so their applicable patient groups and drug resistance conditions are different.

Elagrastrant is mainly used for patients with advanced breast cancer who have previously been treated with aromatase inhibitors and developed resistanceHR+/HER2-. It has been shown in clinical trials that it can delay disease progression and improve progression-free survival (PFS). It is also convenient for oral administration and well tolerated. Everolimus is mostly used in combination therapy when breast cancer patients develop endocrine resistance. It can control tumor growth while prolonging PFS. However, it has relatively many side effects, such as stomatitis, infection risk, pneumonia and metabolic abnormalities.

Common adverse reactions of elastran include hot flashes, nausea, fatigue and joint pain, most of which are mild to moderate and well tolerated by patients, with a low incidence of serious side effects. The side effects of everolimus are relatively more obvious. In addition to the common stomatitis, rash, and infection, there may also be increased blood sugar, lipid abnormalities, and interstitial lung disease, which require more stringent monitoring and management. Better-tolerated drugs are generally better suited for older patients or those with multiple comorbidities.

For HR+/HER2- advanced breast cancer patients, if the main problem is aromatase inhibitor resistance and they want oral treatment and reduce the burden of side effects, elastran may be more suitable; and for patients who have developed endocrine resistance and need combination therapy to delay tumor progression, everolimus still has certain advantages. The final drug selection should be based on the patient's specific condition, drug resistance, comorbid diseases, and financial affordability, and be decided by the attending physician after a comprehensive evaluation.

Reference materials:https://www.drugs.com/